This is in line with other studies showing that in leukemia, prostate cancer and colon cancer the combination of conventional chemotherapy with HDAC inhibitors was able to enhance the effectiveness of therapy substantially [12,30-32]. This evidence concerns the gene HDAC9 and leukemia.